[HTML][HTML] Aspirin in essential thrombocythemia. For whom? What formulation? What regimen?
M Cattaneo - Haematologica, 2023 - ncbi.nlm.nih.gov
Essential thrombocythemia (ET) is a BCR-ABL1-negative myeloproliferative neoplasm, the
most common clinical manifestations of which include arterial and venous thrombosis …
most common clinical manifestations of which include arterial and venous thrombosis …
Application of IPSET-thrombosis in 1366 patients prospectively followed from the Spanish registry of essential thrombocythemia
A Alvarez-Larrán, B Cuevas, P Velez, S Noya… - …, 2023 - journals.lww.com
Abstract The International Prognostic Score of thrombosis in Essential Thrombocythemia
(IPSET-thrombosis) and its revised version have been proposed to guide thrombosis …
(IPSET-thrombosis) and its revised version have been proposed to guide thrombosis …
Prediction of major bleeding events in 1381 patients with essential thrombocythemia
R Stuckey, JC Ianotto, M Santoro, A Czyż… - International Journal of …, 2023 - Springer
The goal of therapy in essential thrombocythemia (ET) is reducing thrombotic risk. No
algorithm to predict hemorrhage risk exists. The impact ofanti-platelet, cytoreductive and …
algorithm to predict hemorrhage risk exists. The impact ofanti-platelet, cytoreductive and …
Aberrant Platelet Aggregation as Initial Presentation of Essential Thrombocythemia: Failure of Entero-Coated Aspirin to Reduce Platelet Hyperactivation
A Morotti, C Barale, M Sornatale, E Giugliano… - International Journal of …, 2023 - mdpi.com
Essential thrombocythemia (ET) is a myeloproliferative neoplasm variant characterized by
excessive production of platelets. Since the most common cause of mortality and morbidity …
excessive production of platelets. Since the most common cause of mortality and morbidity …
The atherogenic index of plasma complicates the thrombotic tendency of chronic myeloproliferative disorders: A retrospective cohort study
M Karadeniz, OO ABACIOGLU, ÜY Malkan… - DAHUDER Medical …, 2023 - dergipark.org.tr
Objectives: Chronic myeloproliferative diseases (CMPD) are neoplastic disorders leading to
hypercoagulability and thrombosis. The critical hemostatic abnormalities include alterations …
hypercoagulability and thrombosis. The critical hemostatic abnormalities include alterations …